David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

May

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans

Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity

ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths

Study Shows Potential Missing Patient Information in SEER Database

Recurrence With Concurrent or Sequential Radiation Dose Escalation to the Surgical Cavity in High-Risk Early Breast Cancer